Inhibition of this pathway has been shown to be sufficient to reverse resistance to Erlotinib in different tumours [195], so the use of specific inhibitors against RALB could be a good strategy in CRC to reverse resistance to EGFR-targeted therapy, especially in those cases in which KRAS inhibition is not possible. This evidence concerns the gene KRAS and colorectal carcinoma.